Arthritis, Juvenile

• 

  Subject Areas on Research

  • 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. 
  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. 
  • 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. 
  • 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. 
  • 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. 
  • 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. 
  • 25-Hydroxyvitamin D therapy in children with active juvenile rheumatoid arthritis: short-term effects on serum osteocalcin levels and bone mineral density. 
  • A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. 
  • A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. 
  • A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. 
  • A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. 
  • Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. 
  • Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. 
  • Adiposity in Juvenile Psoriatic Arthritis. 
  • Adverse Childhood Experiences Are Associated with Childhood-Onset Arthritis in a National Sample of US Youth: An Analysis of the 2016 National Survey of Children's Health. 
  • An i2b2-based, generalizable, open source, self-scaling chronic disease registry. 
  • Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. 
  • Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. 
  • Assessment and treatment of Down syndrome-associated arthritis: a survey of pediatric rheumatologists. 
  • Association of Transition Readiness to Intentional Self-Regulation and Hopeful Future Expectations in Youth With Illness. 
  • Association of the CCR5 gene with juvenile idiopathic arthritis. 
  • Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. 
  • Autoantibodies to DEK oncoprotein in human inflammatory disease. 
  • Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). 
  • Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Blau syndrome and related genetic disorders causing childhood arthritis. 
  • Bone metabolism in childhood rheumatic disease. 
  • Bone mineral status in juvenile rheumatoid arthritis. 
  • Breast feeding and the development of juvenile rheumatoid arthritis. 
  • Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. 
  • CARRA: The Childhood Arthritis and Rheumatology Research Alliance. 
  • Cardiovascular Health in Pediatric Rheumatologic Diseases. 
  • Causes of pain in children with arthritis. 
  • Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. 
  • Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. 
  • Clinical Features and Treatment of Down Syndrome Arthropathy: Experience from Two US Tertiary Hospitals. 
  • Clinical Trial Design in Juvenile Idiopathic Arthritis. 
  • Clinical trials in pediatric rheumatology: comment on the editorial by Lehman. 
  • Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. 
  • Colonic Diverticulitis in a 19-Year-Old Boy With Juvenile Idiopathic Arthritis: Surgical Implications of Chronic Immunosuppression. 
  • Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. 
  • Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease. 
  • Cushing's syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. 
  • Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis. 
  • Daily pain and symptoms in children with polyarticular arthritis. 
  • Daily sleep quality and mood as predictors of pain in children with juvenile polyarticular arthritis. 
  • Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate. 
  • Decreased use of non-steroidal anti-inflammatory drugs for the treatment of juvenile idiopathic arthritis in the era of modern aggressive treatment. 
  • Development of biomarkers to optimize pediatric patient management: what makes children different? 
  • Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. 
  • Down Syndrome-Associated Arthritis Cohort in the New Childhood Arthritis and Rheumatology Research Alliance Registry: Clinical Characteristics, Treatment, and Outcomes. 
  • Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. 
  • Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. 
  • Emotion regulation predicts pain and functioning in children with juvenile idiopathic arthritis: an electronic diary study. 
  • Engaging patients and parents to improve mental health intervention for youth with rheumatological disease. 
  • Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Enthesitis-related arthritis: time to re-define? 
  • Epistasis amongst PTPN2 and genes of the vitamin D pathway contributes to risk of juvenile idiopathic arthritis. 
  • Evidence for linkage of HLA loci in juvenile idiopathic oligoarthritis: independent effects of HLA-A and HLA-DRB1. 
  • Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. 
  • Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. 
  • Familial autoimmunity in the Childhood Arthritis and Rheumatology Research Alliance registry. 
  • Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases. 
  • Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate. 
  • Frequency of abnormal hand and wrist radiographs at time of diagnosis of polyarticular juvenile rheumatoid arthritis. 
  • Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. 
  • Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci. 
  • Goniotomy for glaucoma secondary to chronic childhood uveitis. 
  • Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. 
  • Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis. 
  • Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. 
  • Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. 
  • Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. 
  • Identifying clinically meaningful severity categories for PROMIS pediatric measures of anxiety, mobility, fatigue, and depressive symptoms in juvenile idiopathic arthritis and childhood-onset systemic lupus erythematosus. 
  • If patients are the true north, patient-centeredness should guide research. 
  • Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. 
  • Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. 
  • Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. 
  • Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma. 
  • Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15. 
  • Investigation of rheumatoid arthritis susceptibility loci in juvenile idiopathic arthritis confirms high degree of overlap. 
  • Juvenile arthritis and autoimmunity to type II collagen. 
  • Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study. 
  • Juvenile idiopathic arthritis. 
  • Juvenile rheumatoid arthritis in velo-cardio-facial syndrome: coincidence or unusual complication? 
  • Juvenile rheumatoid arthritis: benefits from massage therapy. 
  • Lack of association between juvenile idiopathic arthritis and fas gene polymorphism. 
  • Linkage and association studies of discoidin domain receptor 1 (DDR1) single nucleotide polymorphisms (SNPs) in juvenile oligoarthritis. 
  • Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis. 
  • Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. 
  • Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. 
  • Massive calcification of the mitral annulus in a 17-year-old patient with juvenile rheumatoid arthritis and systemic lupus erythematosis. 
  • Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Methotrexate: new uses for an old drug. 
  • Monoclonal antibodies that detect biochemical markers of arthritis in humans. 
  • Multisite Randomized Clinical Trial Evaluating an Online Self-Management Program for Adolescents With Juvenile Idiopathic Arthritis. 
  • Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. 
  • Neuroendocrine gene polymorphisms and susceptibility to juvenile idiopathic arthritis. 
  • New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. 
  • Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. 
  • Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro. 
  • Nomenclature and classification in chronic childhood arthritis: time for a change? 
  • Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. 
  • Ophthalmologic examinations in children with juvenile rheumatoid arthritis. 
  • Opioid therapy for the treatment of refractory pain in children with juvenile rheumatoid arthritis. 
  • Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. 
  • Pain as a quality of care measure in juvenile idiopathic arthritis: one step forward, but is it the best foot? Comment on the article by Lovell et al. 
  • Pain coping and the pain experience in children with juvenile chronic arthritis. 
  • Pain in children with arthritis: a review of the current literature. 
  • Pain, stiffness, and fatigue in juvenile polyarticular arthritis: contemporaneous stressful events and mood as predictors. 
  • Parent pain responses as predictors of daily activities and mood in children with juvenile idiopathic arthritis: the utility of electronic diaries. 
  • Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Pediatric Rheumatology Comes of Age: Part I. 
  • Pediatric Rheumatology Comes of Age: Part II. 
  • Pediatric pain syndromes and management of pain in children and adolescents with rheumatic disease. 
  • Peer rejection, social behavior, and psychological adjustment in children with juvenile rheumatic disease. 
  • Periprosthetic fracture between a constrained total knee arthroplasty and a long-stem total hip arthroplasty: treatment with a novel device. 
  • Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study. 
  • Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. 
  • Positive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis. 
  • Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. 
  • Premature cell senescence and T cell receptor-independent activation of CD8+ T cells in juvenile idiopathic arthritis. 
  • Prescribing for Children With Rheumatic Disease: Perceived Treatment Approaches Between Pediatric and Adult Rheumatologists. 
  • Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by prescriber type. 
  • Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. 
  • Profile of adalimumab and its potential in the treatment of uveitis. 
  • Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. 
  • Prominent expression of mRNA for proinflammatory cytokines in synovium in patients with juvenile rheumatoid arthritis or chronic Lyme arthritis. 
  • Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. 
  • Prospective Mediation Models of Sleep, Pain, and Daily Function in Children With Arthritis Using Ecological Momentary Assessment. 
  • Psychometric characteristics of outcome measures in juvenile idiopathic arthritis: a systematic review. 
  • Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. 
  • Radiographic progression in children with polyarticular juvenile rheumatoid arthritis: a pilot study. 
  • Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. 
  • Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability. 
  • Repair of osteopenia in children with juvenile rheumatoid arthritis. 
  • Retroperitoneal fibrosis in children. 
  • Reverse Translation in Advancing Pharmacotherapy in Pediatric Rheumatology: A Logical Approach in Rare Diseases with Limited Resources. 
  • Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis. 
  • Role of alloplastic reconstruction of the temporomandibular joint in the juvenile idiopathic arthritis population. 
  • Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. 
  • Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study. 
  • Sleep quality in children with juvenile rheumatoid arthritis. 
  • Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. 
  • Social functioning and facial expression recognition in survivors of pediatric brain tumors. 
  • Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. 
  • Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. 
  • T Cell Receptor-Independent, CD31/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis. 
  • The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. 
  • The association of PTPN22 rs2476601 with juvenile idiopathic arthritis is specific to females. 
  • The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. 
  • The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. 
  • The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus. 
  • The relationship of daily mood and stressful events to symptoms in juvenile rheumatic disease. 
  • The school experience of children with arthritis. Coping in the 1990s and transition into adulthood. 
  • Therapeutic advancements in juvenile idiopathic arthritis. 
  • Total hip arthroplasty in juvenile rheumatoid arthritis. Two to eleven-year results. 
  • Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. 
  • Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate. 
  • Translating research into practice-implementation recommendations for pediatric rheumatology; Proceedings of the childhood arthritis and rheumatology research alliance 2020 implementation science retreat. 
  • Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. 
  • Treatment of juvenile idiopathic arthritis-associated uveitis: challenges and update. 
  • Treatment of pain in juvenile idiopathic arthritis: a survey of pediatric rheumatologists. 
  • Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. 
  • Tumor necrosis factor blockers in rheumatoid arthritis. 
  • Tumour necrosis factor receptor II polymorphism and juvenile idiopathic arthritis. 
  • Ultrasound versus magnetic resonance imaging of the temporomandibular joint in juvenile idiopathic arthritis: a systematic review. 
  • Update in juvenile rheumatoid arthritis. 
  • Use of tumor necrosis factor inhibitors in uveitis. 
  • Uveitis in children. 
  • Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibility.